Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Theravance, Clinigen Ink Commercialization Agreement In EU For VIBATIV

RELATED NEWS
Trade THRX now with 
3/11/2013 3:57 AM ET

Clinigen Group plc (CLIN.L) and Theravance Inc. (THRX: Quote) have reached an exclusive commercialization agreement in the European Union or EU and certain other countries in Europe for VIBATIV to treat nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus or MRSA when other alternatives are not suitable.

VIBATIV is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as MRSA.

According to the deal, Theravance has granted Clinigen exclusive commercialization rights to VIBATIV in the EU and some other European countries, including Switzerland and Norway. Theravance, in turn, would receive a $5 million upfront payment from Clinigen and is entitled to receive tiered royalties on net sales of VIBATIV, ranging from 20% to 30%. The agreement has a term of at least 15 years, with an option to extend exercisable by Clinigen.

Click here to receive FREE breaking news email alerts for THERAVANCE, INC. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Data storage solutions provider EMC Corp. (EMC) reported that net income attributable to the company for first-quarter 2014 declined to $392 million or $0.19 per share, from $580 million or $0.26 per share in the same quarter last year. Non-GAAP net income attributable to the company was $728 million... U.K. Chancellor George Osborne achieved his budget deficit target for 2013/14 as buoyant economic growth boosted tax receipts. Data from the Office for National Statistics on Wednesday showed that net borrowing totaled GBP 107.7 billion in the fiscal year ended March 2014, the lowest since the 2008/2009 financial crisis. Thailand's central bank left its key interest rate unchanged on Wednesday, after trimming it in the previous month amid the lingering political impasse. The Monetary Policy Committee of the Bank of Thailand voted 6-1 to leave the main policy rate unchanged at 2 percent, which is the lowest level since December 2010. The decision was in line with economists' expectations.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.